Vertex announces reimbursement agreement in spain for kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat people with cystic fibrosis 12 years and older with at least one f508del mutation in the cftr gene

London--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the spanish government has approved terms for the national reimbursement of kaftrio® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) for eligible patients. the agreement covers people with cf ages 12 years and older who have at least one copy of the f508del mutation, regardless of the other mutation type in the cftr gene. kaftrio®
VRTX Ratings Summary
VRTX Quant Ranking